What Does a Positive Signatera Test Mean? | What It Signals

Getting a positive Signatera report can feel scary, even if you’ve been doing well. That reaction makes sense. A Signatera result is one data point, not a full diagnosis on its own.

Signatera is a blood test that looks for circulating tumor DNA (ctDNA). ctDNA is made up of small DNA fragments shed by cancer cells into the bloodstream. For a plain‑language primer on ctDNA “liquid biopsy” testing, the National Cancer Institute’s liquid biopsy overview lays out how these tests work and where they fit in care.

This page shares general information, not personal medical advice. Your oncology team can apply these ideas to your situation.

What Signatera Measures In Your Blood

Blood contains cell‑free DNA from normal cell turnover. If cancer is present, some DNA fragments from cancer cells can appear in that same mix. ctDNA is often present at low levels, so the test is built to pick up a faint tumor signal inside a lot of normal DNA.

Signatera tracks a set of mutations found in a person’s tumor tissue. Later blood draws check for that same mutation pattern. This “tumor‑specific” design is why the test is often used after treatment, when remaining disease can be microscopic.

How A Tumor‑Specific ctDNA Test Is Built

The lab uses tumor tissue to identify mutations that can act like a fingerprint. Many published Signatera studies track up to 16 tumor variants and call a blood sample ctDNA‑positive when at least two tracked variants are detected above a preset confidence threshold. This approach is described in peer‑reviewed research, including a colorectal cancer study in Nature Medicine.

This “two‑variant” rule cuts down the chance that a single stray read becomes a positive call. It also means borderline results can happen when ctDNA levels hover near the cutoff.

What You’ll See On The Report

Most reports give a clear “Positive” or “Negative” call for ctDNA detection. Many also include a value labeled MTM/mL (mean tumor molecules per milliliter of plasma). Natera explains report elements and the meaning of positive and negative calls on the Signatera FAQ page.

If your report has a number, treat it as a trend marker. One isolated value rarely tells the whole story.

What A Positive Signatera Test Result Means After Treatment

A positive result means ctDNA matching your tumor was detected in that blood draw. In early‑stage cancer after surgery or other curative‑intent treatment, this is often described as molecular residual disease (MRD). It suggests cancer cells may still be present, even if imaging is clean. Natera describes a positive Signatera result as MRD and links it with a higher chance of cancer returning in early‑stage disease on its Signatera FAQ.

Across many studies, ctDNA detected after curative‑intent treatment lines up with higher relapse rates than ctDNA‑negative results. In colorectal cancer, the Signatera method and the postoperative timepoints used for tracking are described in the Nature Medicine paper.

Positive Does Not Mean “You Can See It On A Scan”

ctDNA can show up before a CT, PET, or MRI shows a clear lesion. A positive ctDNA result does not tell you where disease is, and it doesn’t replace a scan when your team needs location and anatomy.

What A Positive Result Can’t Tell You By Itself

• Where the disease is. ctDNA is a whole‑body signal, not a map.
• How big it is. The amount can trend up or down, but it isn’t a direct ruler.
• What treatment must happen next. Care decisions still hinge on your stage, prior therapy, scans, and goals.
• How fast things will change. Some rises happen quickly; others move slowly across months.

Positive Does Not Hand You One Automatic Plan

People often want a single rule: positive equals treatment, negative equals no treatment. Clinicians weigh stage, pathology, prior treatments, imaging, and symptoms alongside ctDNA. Sometimes the next step is repeat testing. Sometimes it’s earlier imaging. Sometimes it’s a talk about systemic therapy or a clinical trial tied to ctDNA status.

Why Timing Can Flip The Meaning Of The Same Word

The date of the blood draw matters. Right after surgery or a biopsy, tumor DNA can be released into the bloodstream. Many research protocols collect postoperative samples around four weeks after surgery, and then again later, to reduce short‑term noise. You can see this type of schedule in Signatera‑based studies described in Nature Medicine.

During chemotherapy, immunotherapy, or radiation, ctDNA can move as tumor cells die and as the body clears DNA fragments. That’s one reason serial testing is used: the direction over time can be more telling than a single draw.

When The Positive Result Appears	What It Often Suggests	What To Ask Next
Before curative‑intent treatment	Baseline ctDNA signal	How will it be used later?
0–3 weeks after surgery	Short‑term DNA release or early MRD	When is the repeat draw?
4–12 weeks after surgery	MRD signal in many postoperative schedules	What’s the testing + scan plan?
During adjuvant therapy	Trend can drop or rise during treatment	Are we tracking MTM/mL?
After adjuvant therapy ends	Persistent ctDNA after treatment	How soon to confirm trend?
New positive after months of negatives	Early recurrence signal	When do we repeat and scan?
Positive then negative on the next draw	Borderline signal or variation	Do we need a third draw?
During metastatic treatment	Ongoing disease signal; trend can mirror response	How does it match scans?

How To Read MTM/mL Without Overreacting

If your report lists MTM/mL, it is trying to give your team a consistent yardstick for trend. Natera states that Signatera reports ctDNA quantity as MTM/mL to track disease burden over time on its test FAQ.

A low number can still matter if it rises across repeated draws. A higher number that drops during treatment can line up with response. What counts is the pattern, tied to treatment and scan timing.

Why Two Results Often Beat One

A single positive can happen close to the detection cutoff. That’s why clinicians often confirm a new positive with another blood draw. If ctDNA stays positive at a later timepoint, the signal is harder to dismiss as noise.

If ctDNA flips back to negative, your clinician may keep closer watch and repeat again to see which direction wins out.

Limits, Gray Zones, And Surprise Results

ctDNA testing is a fast‑moving field, and not all uses have the same level of evidence. The FDA has published guidance on using ctDNA in early‑stage solid‑tumor drug development, including MRD assay design topics, on its ctDNA guidance page.

A negative ctDNA result means “not detected in this draw.” It does not prove there is no disease. Some tumors shed less DNA into blood, and shedding can vary across weeks. Small‑volume disease can also be missed when ctDNA is below the test’s detection limit.

Sometimes a positive doesn’t fit the rest of the picture. A draw taken soon after surgery or a procedure can blur timing. A borderline level near the cutoff can flip on repeat. A person with more than one cancer may need separate tracking for each tumor.

Question To Bring To Your Visit	Why It Helps	What To Bring
Which milestone was this draw tied to?	Timing shapes interpretation	Treatment dates
Is this the first positive, or a repeat?	Repeat positives carry more weight	Prior reports
What is the MTM/mL value and trend?	Trend guides next steps	Dates + values list
When will we repeat the blood draw?	Confirms direction	Your availability
Will imaging be moved earlier?	Helps locate disease	Last scan results
Does my cancer shed ctDNA reliably?	Sensitivity varies	Pathology, stage
Are trials tied to ctDNA status an option?	Some trials assign therapy by MRD status	Prior treatments list
How will I get results and ask questions?	Sets expectations	Portal + clinic contacts

Next Steps After A Positive Signatera Result

Most plans after a positive result follow the same rhythm: confirm, pair with imaging when needed, then decide whether the plan changes. Your clinician will tailor that rhythm to your cancer type and treatment window.

One practical move is building a one‑page timeline. List surgery date, treatment cycles, scan dates, and Signatera draws. Bring it to the visit. It helps your clinician line up the ctDNA trend with the rest of your care.

Start With A Simple Checklist

• Write down the draw date and what was happening in treatment that week.
• Ask for the MTM/mL value (if reported) and prior values.
• Ask when a repeat draw is planned and what timing makes sense.
• Ask if scan timing will change.
• Share recent procedures, infections, or transfusions.

How Clinicians Often Confirm A New Positive

If you’re on surveillance and ctDNA turns positive, a common next step is a repeat test after a short interval, plus imaging sooner than originally planned. If you’re in active treatment, the ctDNA trend is often weighed alongside scan response and how you feel.

Ask your team what will count as “confirmed” in your case. Some plans treat two positives in a row as a stronger trigger for action. Others weigh ctDNA and imaging together before any change.

Putting The Result Into Context

A positive Signatera result means ctDNA matching your tumor was detected in your blood. In many early‑stage settings, that aligns with MRD and a higher relapse risk, even when scans are clean. What matters next is timing, the MTM/mL trend, and the plan your oncology team uses to confirm the signal.

If you bring the right questions to your next visit, you can turn a scary report into a concrete plan—repeat testing, earlier imaging, treatment, or a trial option.